4.6 Article

Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson's models

期刊

ACTA NEUROPATHOLOGICA
卷 136, 期 4, 页码 607-620

出版社

SPRINGER
DOI: 10.1007/s00401-018-1873-4

关键词

Parkinson; Alpha-synuclein; Miro; Mitochondria; Mitophagy; iPSC; Fly; Dopaminergic

资金

  1. California Institute for Regenerative Medicine [GC1R-06673-A]
  2. Michael J. Fox Foundation
  3. Esther A. and Joseph Klingenstein Fund
  4. California Institute of Regenerative Medicine
  5. National Institute of Health [RO1NS089583]
  6. Archer Fund
  7. NINDS (National Brain and Tissue Resource for Parkinson's Disease and Related Disorders) [U24 NS072026]
  8. National Institute on Aging (Arizona Alzheimer's Disease Core Center) [P30 AG19610]
  9. Arizona Department of Health Services (Arizona Alzheimer's Research Center) [211002]
  10. Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001]

向作者/读者索取更多资源

Alpha-synuclein is a component of Lewy bodies, the pathological hallmark of Parkinson's disease (PD), and is also mutated in familial PD. Here, by extensively analyzing PD patient brains and neurons, and fly models, we show that alpha-synuclein accumulation results in upregulation of Miro protein levels. Miro is a motor/adaptor on the outer mitochondrial membrane that mediates mitochondrial motility, and is removed from damaged mitochondria to facilitate mitochondrial clearance via mitophagy. PD patient neurons abnormally accumulate Miro on the mitochondrial surface leading to delayed mitophagy. Partial reduction of Miro rescues mitophagy phenotypes and neurodegeneration in human neurons and flies. Upregulation of Miro by alpha-synuclein requires an interaction via the N-terminus of alpha-synuclein. Our results highlight the importance of mitochondria-associated alpha-synuclein in human disease, and present Miro as a novel therapeutic target.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据